Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Tivic Health Systems ( (TIVC) ).
On March 18, 2025, Tivic Health Systems entered into an Equity Purchase Agreement with Mast Hill Fund, allowing Tivic to sell up to $25 million in common stock over 24 months. This agreement provides Tivic with financial flexibility to support its strategic initiatives, including expanding its biopharmaceutical program and advancing its non-invasive cervical vagus nerve stimulation devices. The company also reported a 30% reduction in net loss for 2024, reflecting improved financial management. Tivic’s recent strategic moves, including acquiring rights to Entolimod™ and appointing new leadership, aim to enhance its market position and drive growth in the biotech sector.
More about Tivic Health Systems
Tivic Health Systems is a diversified therapeutics company focusing on harnessing the immune and autonomic nervous systems to combat disease and promote health. The company develops non-invasive medical devices, such as the FDA-approved ClearUP® for sinus pain, and is advancing its bioelectronic program with a focus on non-invasive vagus nerve stimulation. Additionally, Tivic is expanding into drug development with its biologic program, featuring the late-stage TLR5 agonist, Entolimod™, for treating acute radiation syndrome.
YTD Price Performance: -40.82%
Average Trading Volume: 748,896
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.93M
Learn more about TIVC stock on TipRanks’ Stock Analysis page.